Incyte (INCY) revenue

Revenue · fiscal 2025
$5.14B

Incyte (INCY) reported revenue of $5.14B in fiscal 2025 (the year ended December 31, 2025). That is 21.2% higher than the $4.24B of fiscal 2024. Figures as of 18 Nov 2026, 09:39 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2025
$5.14B
Change on fiscal 2024
+21.2%
Growth, 5 years
+14.0% a year
Growth, 10 years
+21.2% a year
Highest on record
$5.14Bfiscal 2025
Lowest on record
$9.27Mfiscal 2009
Fiscal years on record
172009–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Incyte revenue, in more detail

Over the five fiscal years to 2025 revenue grew at a compound 14.0% a year; over ten years the rate was 21.2% a year. Across the 17 fiscal years on record (2009–2025), the highest was $5.14B in fiscal 2025 and the lowest $9.27M in fiscal 2009.

History · 17 fiscal years

Revenue by fiscal year

Incyte revenue, year by year

Incyte (INCY) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2025$5.14B 21.2% up
2024$4.24B 14.8% up
2023$3.70B 8.9% up
2022$3.39B 13.7% up
2021$2.99B 12.0% up
2020$2.67B 23.5% up
2019$2.16B 14.7% up
2018$1.88B 22.5% up
2017$1.54B 38.9% up
2016$1.11B 46.7% up
2015$753.75M 47.4% up
2014$511.50M 44.1% up
2013$354.95M 19.5% up
2012$297.06M 214.5% up
2011$94.46M 44.4% down
2010$169.88M 1,733.5% up
2009$9.27M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

Revenue at health care companies of similar size

Revenue of Incyte and comparable companies
CompanyRevenueFiscal year
STERIS STE$5.94B2026
Insmed INSM$606.42M2025
United Therapeutics UTHR$3.18B2025
Incyte INCY$5.14B2025
Viatris VTRS$14.30B2025
Tenet Healthcare THC$21.31B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on INCY

Incyte, figure by figure

Incyte (INCY) overview: price, valuation and scorecardAll health care companies by market value

Incyte revenue: questions and answers

What is Incyte's revenue?

Incyte (INCY) reported revenue of $5.14B in fiscal 2025 (the year ended December 31, 2025). That is 21.2% higher than the $4.24B of fiscal 2024.

What is the growth rate of Incyte's revenue?

Over the five fiscal years to 2025 revenue grew at a compound 14.0% a year; over ten years the rate was 21.2% a year.

What are the highest and lowest revenue figures on record for Incyte?

Across the 17 fiscal years on record (2009–2025), the highest was $5.14B in fiscal 2025 and the lowest $9.27M in fiscal 2009.

How is Incyte's revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Incyte it is on record here for 17 fiscal years, 2009 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Incyte (INCY) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/INCY/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.